Printer Friendly

ISIS OBTAINS OPTION ON ANTISENSE OLIGONUCLEOTIDES THAT INHIBIT EXPRESSION OF PROTEIN RESPONSIBLE FOR CHRONIC EPSTEIN-BARR INFECTION

    ISIS OBTAINS OPTION ON ANTISENSE OLIGONUCLEOTIDES THAT INHIBIT EXPRESSION OF PROTEIN RESPONSIBLE FOR CHRONIC EPSTEIN-BARR INFECTION
    CARLSBAD, Calif., Nov. 13 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) reported today that it entered into an option agreement with the University of North Carolina at Chapel Hill for a license to antisense oligomers directed against the EBNA-1 protein that is responsible for latent (chronic) Epstein-Barr viral (EBV) infections. Latent EBV infections are associated with nasopharyngeal carcinomas and Burkitt's lymphoma, and the oligomers will be developed for the prevention or treatment of these malignancies.
    Dr. Joseph Pagano, director of the Lineberger Cancer Center at the University of North Carolina, together with other members of his laboratory, invented the oligonucleotides.  Pagano has had a collaborative relationship with Isis scientists for over one year, and the two laboratories continue to work together.
    Located in Northern San Diego County, Isis is engaged in the discovery, development and marketing of novel human therapeutic products based on antisense technology.
    -0-           11/13/91
    /CONTACT:  B. Lynne Parshall, vice president of Isis, 619-931-9200, or Anthony J. Russo or Deborah J. Lawson of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
    (ISIP) CO:  Isis Pharmaceuticals, Inc.; University of North Carolina ST:  California, North Carolina IN:  MTC SU:  LIC JT -- NY085 -- 4101 11/13/91 16:28 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:215
Previous Article:PSE&G EXPECTS INSURANCE TO EASE FINANCIAL IMPACT OF SALEM 2 SHUTDOWN
Next Article:GENERAL MOTORS REPORTS SALES
Topics:


Related Articles
ISIS RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS ON ANTISENSE HPV DRUG
ISIS PHARMACEUTICALS DISCOVERS NEW BINDING TECHNIQUE
ISIS AND CIBA FINALIZE MAJOR EXPANDED ANTISENSE RESEARCH AND DEVELOPMENT AGREEMENT; A SECOND CANCER COMPOUND SET TO ENTER PHASE I CLINICAL TRIALS
Hybridon Signs Research Collaborations with Leading Medical Institutions In Paris and Oslo to Develop Antisense Therapies for Asthma and Cancer
Hybridon and UNC Researchers Demonstrate First Use of Antisense Technology in Correcting Gene Function Inside Cell Nucleus
Isis Shows Second Generation Chemistry Increases Potency And Validates Novel Antisense Mechanism of Action
OncoGenex, Isis expand antisense anti-cancer drug collaboration.
New patent adds to Hybridon's antisense chemistry patent portfolio.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters